185 related articles for article (PubMed ID: 20826478)
1. Regenerative nanomedicines: an emerging investment prospective?
Prescott C
J R Soc Interface; 2010 Dec; 7 Suppl 6(Suppl 6):S783-7. PubMed ID: 20826478
[TBL] [Abstract][Full Text] [Related]
2. Trends in the stem cell and regenerative medicine industry.
Ilic D
Regen Med; 2012 Sep; 7(5):645-8. PubMed ID: 22954435
[TBL] [Abstract][Full Text] [Related]
3. REGENERATIVE MEDICINE. California stem cell agency plots a race to the clinic.
Servick K
Science; 2016 Jan; 351(6268):15. PubMed ID: 26721984
[No Abstract] [Full Text] [Related]
4. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
[TBL] [Abstract][Full Text] [Related]
5. Stem cell research in Latin America: update, challenges and opportunities in a priority research area.
Palma V; Pitossi FJ; Rehen SK; Touriño C; Velasco I
Regen Med; 2015; 10(6):785-98. PubMed ID: 26440367
[TBL] [Abstract][Full Text] [Related]
6. [Stem cells: scientific progress and commercial tactics].
Nau JY
Rev Med Suisse; 2013 Oct; 9(400):1794-5. PubMed ID: 24187755
[No Abstract] [Full Text] [Related]
7. 2010 World Stem Cell Summit--part 1. October 4-6, 2010, Detroit, MI, USA.
Vertès A
IDrugs; 2010 Dec; 13(12):819-21. PubMed ID: 21154132
[TBL] [Abstract][Full Text] [Related]
8. Tissue engineering and regenerative medicine: manufacturing challenges.
Williams DJ; Sebastine IM
IEE Proc Nanobiotechnol; 2005 Dec; 152(6):207-10. PubMed ID: 16441181
[TBL] [Abstract][Full Text] [Related]
9. California: 'the Stem Cell State'. Interview with Jonathan Thomas.
Thomas J
Regen Med; 2011 Nov; 6(6 Suppl):113-5. PubMed ID: 21999272
[TBL] [Abstract][Full Text] [Related]
10. Tech news: stem cells for modeling and curing disease.
Leask F
Biotechniques; 2018 Dec; 65(6):305-310. PubMed ID: 30477326
[TBL] [Abstract][Full Text] [Related]
11. Value-engineered translation for regenerative medicine: meeting the needs of health systems.
Bubela T; McCabe C
Stem Cells Dev; 2013 Dec; 22 Suppl 1(Suppl 1):89-93. PubMed ID: 24304083
[TBL] [Abstract][Full Text] [Related]
12. Why regenerative stem cell medicine progresses slower than expected.
Rosemann A
J Cell Biochem; 2014 Dec; 115(12):2073-6. PubMed ID: 25079695
[No Abstract] [Full Text] [Related]
13. Regenerative medicine. Opportunities and challenges: a brief overview.
Polak DJ
J R Soc Interface; 2010 Dec; 7 Suppl 6(Suppl 6):S777-81. PubMed ID: 20826477
[TBL] [Abstract][Full Text] [Related]
14. The NIH and the regenerative medicine field.
Rao M
Regen Med; 2012 Mar; 7(2):129-31. PubMed ID: 22397601
[No Abstract] [Full Text] [Related]
15. Industry updates from the field of stem cell research and regenerative medicine in March 2020.
Ilic D; Liovic M
Regen Med; 2020 Jul; 15(7):1833-1840. PubMed ID: 32452720
[TBL] [Abstract][Full Text] [Related]
16. Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1-31 March 2017.
Ilic D; Berengueras JM
Regen Med; 2017 Jul; 12(5):479-486. PubMed ID: 28722542
[No Abstract] [Full Text] [Related]
17. [What is Nanomedicine? Nanotechnology for most of the patients!].
Müller B
Rev Med Suisse; 2012 Jan; 8(325):152-3. PubMed ID: 22338491
[No Abstract] [Full Text] [Related]
18. Global update: Scotland.
Courtney A
Regen Med; 2011 Nov; 6(6 Suppl):150-2. PubMed ID: 21999279
[TBL] [Abstract][Full Text] [Related]
19. Regenerative medicine: the emergence of an industry.
Nerem RM
J R Soc Interface; 2010 Dec; 7 Suppl 6(Suppl 6):S771-5. PubMed ID: 20843840
[TBL] [Abstract][Full Text] [Related]
20. California's vote to revive controversial stem-cell institute sparks debate.
Subbaraman N
Nature; 2020 Nov; 587(7835):535. PubMed ID: 33199902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
